ArticleLangenbeck's archives of surgery2026
Outcome of segmentectomy vs. lobectomy in patients with cT1a-b N0 lung cancer and postoperative N1 upstaging.
Article in Langenbeck's archives of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSegmentectomy is offered in selected patients with clinical T1a-b N0 M0 lung cancer. In case of positive N1 lymph node at fresh frozen section, conversion to lobectomy is recommended. Indication for redo surgery and completion lobectomy in case of positive N1 lymph node at final pathology is highly debated. We aim to compare the outcome between segmentectomy and lobectomy in patients with cT1a-b N0 M0 lung cancer with postoperative N1-upstaging.
methodsWe retrospectively reviewed all patients with pT1a-b N1cM0 lung cancer who underwent surgical resection with lymph node dissection between January 2013 and January 2024 at our institution. We included patients with tumor size ≤ 2 cm and postoperative N1-upstaging. Disease-free (DFS) and overall (OS) survivals were calculated from the date of surgery until recurrence or death and were compared between the groups.
resultsTwenty-five patients with cT1a-b N0 M0 lung cancer and postoperative N1-upstaging were identified. Median age was 64 years (42-81). Sixteen (64%) patients underwent lobectomy There was no significant difference in tumor size (median: 1,1, IQR[Formula: see text]1,1-1,8[Formula: see text] vs. 1,5, IQR[Formula: see text]1,4 - 1,8[Formula: see text], p = 0.186) and FEV1% (median: 76, IQR[Formula: see text]74- 92[Formula: see text] vs. 75, IQR[Formula: see text]69- 87[Formula: see text], p = 0.656) between segmentectomy and lobectomy groups. Number of lymph nodes removed was significantly lower in the segmentectomy group (median: 10, IQR[Formula: see text]4- 26[Formula: see text] vs. 23, IQR[Formula: see text]14- 32[Formula: see text] p = 0.035). Median follow-up was 53, IQR[Formula: see text]41- 63[Formula: see text] months. There was no difference in 5-year DFS (72.9%vs 70.5%, p = 0.502) and OS (85,7%vs. 85,6%, p = 0.233) between the groups.
conclusionIn patients who underwent segmentectomy or lobectomy for cT1a-b N0 M0 lung cancer and postoperative N1-upstaging, no difference in survivals was seen in our cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.